Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06256536
Status:
COMPLETED
Last Update Posted:
2024-02-23
First Post:
2024-02-05
Brief Title:
A Study of GZR18 Injection in Chinese ObeseOverweight Patients
Sponsor:
Gan and Lee Pharmaceuticals USA
Organization:
Gan and Lee Pharmaceuticals USA
Study Overview
Official Title:
A Multicenter Randomized Double-blind Placebo-controlled Phase IbIIa Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of GZR18 Injection in Chinese ObeseOverweight Patients
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study was a multicenter randomized double-blind placebo-controlled phase IbIIa clinical study to evaluate the safety tolerability pharmacokinetics and efficacy of GZR18 injection in Chinese adult obeseoverweight patients This study is divided into Part A and Part B which are to be conducted simultaneously
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None